Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden

. Ahlbeck Glader C, Slunga Birgander L, Stenlund H, Dahlén GH (Umeå University, Umeå, Sweden). Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med 2002; 252: 27–35. Objectives. Lipoprotein(a) [Lp(a)] is a known risk factor for the development of atherosclerosis. The aim of the present study was to test the importance of Lp(a) as a predictor for the further prognosis in patients with established coronary artery disease. Design. A prospective patient cohort study was carried out. Setting and subjects. The cohort consists of 1216 patients who were examined with coronary angiography at the University Hospital in Umeå, Sweden, because of stable effort angina. Main outcome measures. Lipids, Lp(a), fibrinogen, antithrombin III (AT III), sedimentation rate and clinical data were registered at angiography. After a mean follow‐up time of 6.7 years information on survival was collected from the municipal census lists and death certificates were examined. Total mortality and mortality because of cardiovascular disease were both used as outcome variables in the survival analyses. Results. The total mortality in the patient cohort was 16.4%. An Lp(a) level of 300 mg L−1 or more was found in 30% of the study population and was found to be an independent predictor for death. A high fibrinogen, a low AT III level, a depressed left ventricular function and a high coronary obstruction score were other significant independent predictors of death. Total cholesterol, HDL‐ and LDL‐cholesterol were not related to survival in this study, but a substantial proportion of the population probably received lipid‐lowering agents during the study period. Conclusions. An Lp(a) level exceeding 300 mg L−1 indicates a poor further prognosis and may help to identify patients who probably need powerful secondary prevention programmes to improve their prognosis.